JP2004504388A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004504388A5 JP2004504388A5 JP2002514115A JP2002514115A JP2004504388A5 JP 2004504388 A5 JP2004504388 A5 JP 2004504388A5 JP 2002514115 A JP2002514115 A JP 2002514115A JP 2002514115 A JP2002514115 A JP 2002514115A JP 2004504388 A5 JP2004504388 A5 JP 2004504388A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- phenyl
- dichloro
- amide according
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001408 amides Chemical class 0.000 claims 19
- 229910052760 oxygen Inorganic materials 0.000 claims 15
- 229910052717 sulfur Chemical group 0.000 claims 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 11
- 239000001301 oxygen Substances 0.000 claims 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000011593 sulfur Chemical group 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 150000001721 carbon Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 229910002091 carbon monoxide Inorganic materials 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 229910052757 nitrogen Chemical group 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003568 thioethers Chemical class 0.000 claims 2
- XTDQXQIDBRVLFJ-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-2-(oxan-4-yloxy)-n-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1SC=CN=1)OC1CCOCC1 XTDQXQIDBRVLFJ-UHFFFAOYSA-N 0.000 claims 1
- MIEVEFJYIVXWLB-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-n-(methylcarbamoyl)-2-(oxan-4-yloxy)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCOCC1 MIEVEFJYIVXWLB-UHFFFAOYSA-N 0.000 claims 1
- LNNBWXQTZQJUMS-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfonylphenyl)-2-cyclohex-2-en-1-yloxy-n-(4,5-dihydro-1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SCCN=1)OC1C=CCCC1 LNNBWXQTZQJUMS-UHFFFAOYSA-N 0.000 claims 1
- AKTVVVWFNHFFQE-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfonylphenyl)-2-cyclohex-2-en-1-yloxy-n-(methylcarbamoyl)acetamide Chemical compound C=1C=C(S(C)(=O)=O)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCC=C1 AKTVVVWFNHFFQE-UHFFFAOYSA-N 0.000 claims 1
- CNNNBBYSLRJXCB-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfonylphenyl)-2-cyclopentyloxy-n-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)OC1CCCC1 CNNNBBYSLRJXCB-UHFFFAOYSA-N 0.000 claims 1
- GDLVELQZXTUWHH-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfonylphenyl)-2-cyclopentyloxy-n-(methylcarbamoyl)acetamide Chemical compound C=1C=C(S(C)(=O)=O)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCC1 GDLVELQZXTUWHH-UHFFFAOYSA-N 0.000 claims 1
- OKVVHUTYWMKAMT-UHFFFAOYSA-N 2-cyclohex-2-en-1-yloxy-2-(3,4-dichlorophenyl)-n-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1SC=CN=1)OC1C=CCCC1 OKVVHUTYWMKAMT-UHFFFAOYSA-N 0.000 claims 1
- GBRFVNIVLOASHK-UHFFFAOYSA-N 2-cyclohex-2-en-1-yloxy-2-(3,4-dichlorophenyl)-n-(methylcarbamoyl)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCC=C1 GBRFVNIVLOASHK-UHFFFAOYSA-N 0.000 claims 1
- MMNSTTDMQWXPIG-UHFFFAOYSA-N 2-cyclohexyloxy-2-(3,4-dichlorophenyl)-n-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1SC=CN=1)OC1CCCCC1 MMNSTTDMQWXPIG-UHFFFAOYSA-N 0.000 claims 1
- PZDFZWWTLUQGLV-UHFFFAOYSA-N 2-cyclohexyloxy-2-(3,4-dichlorophenyl)-n-(methylcarbamoyl)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCCC1 PZDFZWWTLUQGLV-UHFFFAOYSA-N 0.000 claims 1
- POASZSTXBAHPDO-UHFFFAOYSA-N 2-cyclopentyloxy-2-(3,4-dichlorophenyl)-n-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1SC=CN=1)OC1CCCC1 POASZSTXBAHPDO-UHFFFAOYSA-N 0.000 claims 1
- AQFOGDIAJYVUPT-UHFFFAOYSA-N 2-cyclopentyloxy-2-(3,4-dichlorophenyl)-n-(methylcarbamoyl)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCC1 AQFOGDIAJYVUPT-UHFFFAOYSA-N 0.000 claims 1
- VDMFSJBFMOBHGB-UHFFFAOYSA-N 2-cyclopentyloxy-2-(3,4-dichlorophenyl)-n-pyridin-2-ylacetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1N=CC=CC=1)OC1CCCC1 VDMFSJBFMOBHGB-UHFFFAOYSA-N 0.000 claims 1
- WAUWSYSGLFXHRD-UHFFFAOYSA-N 2-cyclopentylsulfonyl-2-(3,4-dichlorophenyl)-n-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(S(=O)(=O)C1CCCC1)C(=O)NC1=NC=CS1 WAUWSYSGLFXHRD-UHFFFAOYSA-N 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- UMLQXVZOFOAQFB-UHFFFAOYSA-N 3-cyclopentyl-2-(3,4-dichlorophenyl)-3-oxo-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)C1CCCC1)C(=O)NC1=NC=CS1 UMLQXVZOFOAQFB-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- -1 alkali metal alkoxide Chemical class 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000005595 deprotonation Effects 0.000 claims 1
- 238000010537 deprotonation reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21987200P | 2000-07-20 | 2000-07-20 | |
| PCT/EP2001/007994 WO2002008209A1 (en) | 2000-07-20 | 2001-07-11 | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004504388A JP2004504388A (ja) | 2004-02-12 |
| JP2004504388A5 true JP2004504388A5 (cg-RX-API-DMAC7.html) | 2005-02-17 |
| JP4138478B2 JP4138478B2 (ja) | 2008-08-27 |
Family
ID=22821104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002514115A Expired - Fee Related JP4138478B2 (ja) | 2000-07-20 | 2001-07-11 | アルファ−アシル及びアルファ−ヘテロ原子置換ベンゼンアセトアミドのグルコキナーゼアクチベーター |
Country Status (21)
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| EP1336607A1 (en) * | 2002-02-19 | 2003-08-20 | Novo Nordisk A/S | Amide derivatives as glucokinase activators |
| WO2003055482A1 (en) * | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Amide derivatives as gk activators |
| AU2003232204B8 (en) * | 2002-04-26 | 2009-07-30 | F. Hoffmann-La Roche Ag | Substituted phenylacetamides and their use as glucokinase activators |
| PL215132B1 (pl) | 2002-06-27 | 2013-10-31 | Novo Nordisk As | Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca |
| KR101124245B1 (ko) | 2002-06-27 | 2012-07-02 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
| WO2004050645A1 (en) * | 2002-10-03 | 2004-06-17 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| WO2004063194A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Heteroaryl compounds |
| PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| EP1670815A2 (en) | 2003-09-30 | 2006-06-21 | Novo Nordisk A/S | Melanocortin receptor agonists |
| DE602004031455D1 (de) | 2003-12-09 | 2011-03-31 | Novo Nordisk As | Regulierung der nahrungspräferenz mit glp-1-agonisten |
| MXPA06007667A (es) | 2004-01-06 | 2006-09-01 | Novo Nordisk As | Heteroaril-ureas y su uso como activadores de glucocinasa. |
| EP1735322B1 (en) | 2004-04-02 | 2011-09-14 | Novartis AG | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful for the treatment of type 2 diabetes |
| BRPI0509543A (pt) | 2004-04-02 | 2007-09-18 | Novartis Ag | derivados de tiazolopiridina, condições farmacêuticas que contêm os mesmos e métodos para tratar condições mediadas por glucocinase |
| MXPA06012008A (es) * | 2004-04-21 | 2007-01-25 | Prosidion Ltd | Compuestos de amida tri(ciclo) sustituidos. |
| UA90264C2 (ru) * | 2004-04-21 | 2010-04-26 | Прозидион Лтд. | Три(цикло)замещенные амиды, фармацевтическая композиция, способы лечения и профилактики, способ получения соединения |
| CN1950078A (zh) | 2004-06-11 | 2007-04-18 | 诺和诺德公司 | 使用glp－1激动剂抵抗药物诱发的肥胖 |
| GB0418046D0 (en) * | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
| CN101035767A (zh) * | 2004-08-12 | 2007-09-12 | 普洛希典有限公司 | 被取代的苯乙酰胺及其作为葡糖激酶激活剂的用途 |
| JP2009500377A (ja) * | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー／エス | ジシクロアルキルウレア型グルコキナーゼ活性化剤 |
| EP1904438B1 (en) | 2005-07-08 | 2012-02-29 | Novo Nordisk A/S | Dicycloalkylcarbamoyl ureas as glucokinase activators |
| EP2301935A1 (en) | 2005-07-09 | 2011-03-30 | AstraZeneca AB (Publ) | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| CN101263131B (zh) | 2005-07-14 | 2013-04-24 | 特兰斯特克药品公司 | 脲葡糖激酶活化剂 |
| US8106090B2 (en) | 2005-07-20 | 2012-01-31 | Eli Lilly And Company | 1-amino linked compounds |
| CA2621227A1 (en) | 2005-08-31 | 2007-03-08 | Astellas Pharma Inc. | Thiazole derivative |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| CN101272784A (zh) | 2005-09-29 | 2008-09-24 | 塞诺菲-安万特股份有限公司 | 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途 |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| GT200600428A (es) | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| BRPI0618062A2 (pt) * | 2005-11-03 | 2011-08-16 | Prosidion Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto |
| AU2006342449B2 (en) | 2005-11-17 | 2012-03-01 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
| US20070197532A1 (en) * | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
| WO2007104034A2 (en) | 2006-03-08 | 2007-09-13 | Takeda San Diego, Inc. | Glucokinase activators |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP2049518B1 (en) | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| US8022066B2 (en) | 2006-11-15 | 2011-09-20 | High Point Pharmaceuticals, Llc | 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
| US7902248B2 (en) | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
| WO2008079787A2 (en) | 2006-12-20 | 2008-07-03 | Takeda San Diego, Inc. | Glucokinase activators |
| TW200831081A (en) * | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| WO2008084043A1 (en) | 2007-01-09 | 2008-07-17 | Novo Nordisk A/S | Urea glucokinase activators |
| JP5226008B2 (ja) | 2007-01-11 | 2013-07-03 | ノボ・ノルデイスク・エー／エス | ウレアグルコキナーゼアクチベーター |
| WO2008104994A2 (en) | 2007-02-28 | 2008-09-04 | Advinus Therapeutics Private Limited | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application |
| WO2008111473A1 (ja) * | 2007-03-07 | 2008-09-18 | Kyorin Pharmaceutical Co., Ltd. | グルコキナーゼ活性化物質 |
| WO2008116107A2 (en) * | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
| AU2008310519B2 (en) * | 2007-10-08 | 2013-05-02 | Advinus Therapeutics Private Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| US9340506B2 (en) | 2007-10-08 | 2016-05-17 | Advinus Therapeutics Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| AR070107A1 (es) * | 2008-01-15 | 2010-03-17 | Lilly Co Eli | R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia |
| KR20100113518A (ko) | 2008-01-18 | 2010-10-21 | 아스텔라스세이야쿠 가부시키가이샤 | 페닐아세트아미드 유도체 |
| JP5449144B2 (ja) | 2008-04-28 | 2014-03-19 | 杏林製薬株式会社 | シクロペンチルアクリル酸アミド誘導体 |
| EA018988B1 (ru) | 2008-05-16 | 2013-12-30 | Такеда Калифорния, Инк. | Активаторы глюкокиназы |
| US8450494B2 (en) | 2009-06-22 | 2013-05-28 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (GK) activators |
| DK2459554T3 (da) | 2009-07-31 | 2014-01-06 | Cadila Healthcare Ltd | Substituerede benzamidderivater som glucokinase (GK)-aktivatorer |
| WO2011080755A1 (en) | 2009-12-29 | 2011-07-07 | Advinus Therapeutics Private Limited | Fused nitrogen heterocyclic compounds, process of preparation and uses thereof |
| WO2011095997A1 (en) | 2010-02-08 | 2011-08-11 | Advinus Therapeutics Private Limited | Benzamide compounds as glucokinase activators and their pharmaceutical application |
| US20130012432A1 (en) | 2010-02-26 | 2013-01-10 | Novo Nordisk A/S | Peptides for Treatment of Obesity |
| BR112012021231A2 (pt) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto |
| AU2011231503C1 (en) | 2010-03-26 | 2016-03-03 | Novo Nordisk A/S | Novel glucagon analogues |
| ES2893699T3 (es) | 2010-03-31 | 2022-02-09 | Scripps Research Inst | Reprogramación de células |
| EP2402327B1 (en) | 2010-06-29 | 2018-03-07 | Impetis Biosciences Ltd. | Acetamide compounds as glucokinase activators, their process and medicinal applications |
| CA2830974A1 (en) | 2011-03-28 | 2012-10-04 | Jesper F. Lau | Novel glucagon analogues |
| TWI596110B (zh) | 2011-09-23 | 2017-08-21 | 諾佛 儂迪克股份有限公司 | 新穎升糖素類似物 |
| PL2986313T3 (pl) | 2013-04-18 | 2019-12-31 | Novo Nordisk A/S | Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych |
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| CN111032680A (zh) | 2017-03-15 | 2020-04-17 | 诺和诺德股份有限公司 | 能够与黑皮质素4受体结合的双环化合物 |
| US20210221867A1 (en) | 2018-05-15 | 2021-07-22 | Novo Nordisk A/S | Compounds Capable of Binding to Melanocortin 4 Receptor |
| MX2020008905A (es) | 2018-06-12 | 2020-12-03 | Vtv Therapeutics Llc | Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas. |
| WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| WO2021252311A1 (en) | 2020-06-08 | 2021-12-16 | Vtv Therapeutics Llc | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
| CN117209448A (zh) * | 2023-09-13 | 2023-12-12 | 济宁医学院 | 含(苯并)噻唑硫代/硒代乙酰胺及其衍生物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3776917A (en) * | 1972-06-05 | 1973-12-04 | Schering Corp | 2-amino-6-phenalkyl-aminopyridines and derivatives thereof |
| JPS5564592A (en) * | 1978-11-10 | 1980-05-15 | Teijin Ltd | Thiazolo 3, 2-a pyrimidine derivative, its preparation, and drug comprising it |
| JPS62153273A (ja) * | 1985-12-26 | 1987-07-08 | Tokuyama Soda Co Ltd | ピラゾ−ル化合物 |
| PT1169312E (pt) * | 1999-03-29 | 2005-01-31 | Hoffmann La Roche | Activadores de glicocinase |
-
2001
- 2001-07-11 WO PCT/EP2001/007994 patent/WO2002008209A1/en not_active Ceased
- 2001-07-11 AT AT01967150T patent/ATE297907T1/de not_active IP Right Cessation
- 2001-07-11 AU AU2001287600A patent/AU2001287600B2/en not_active Ceased
- 2001-07-11 JP JP2002514115A patent/JP4138478B2/ja not_active Expired - Fee Related
- 2001-07-11 PT PT01967150T patent/PT1305301E/pt unknown
- 2001-07-11 MX MXPA03000365A patent/MXPA03000365A/es active IP Right Grant
- 2001-07-11 AU AU8760001A patent/AU8760001A/xx active Pending
- 2001-07-11 ES ES01967150T patent/ES2243547T3/es not_active Expired - Lifetime
- 2001-07-11 DE DE60111534T patent/DE60111534T2/de not_active Expired - Lifetime
- 2001-07-11 CA CA002416229A patent/CA2416229C/en not_active Expired - Fee Related
- 2001-07-11 BR BR0112658-0A patent/BR0112658A/pt not_active IP Right Cessation
- 2001-07-11 KR KR1020037000822A patent/KR100556323B1/ko not_active Expired - Fee Related
- 2001-07-11 DK DK01967150T patent/DK1305301T3/da active
- 2001-07-11 CN CNB01813050XA patent/CN1184214C/zh not_active Expired - Fee Related
- 2001-07-11 EP EP01967150A patent/EP1305301B1/en not_active Expired - Lifetime
- 2001-07-13 US US09/905,152 patent/US6486184B2/en not_active Expired - Fee Related
- 2001-07-18 AR ARP010103437A patent/AR032626A1/es active IP Right Grant
- 2001-07-18 PA PA20018522701A patent/PA8522701A1/es unknown
- 2001-07-19 UY UY26850A patent/UY26850A1/es not_active Application Discontinuation
- 2001-07-19 PE PE2001000731A patent/PE20020335A1/es not_active Application Discontinuation
- 2001-07-20 GT GT200100146A patent/GT200100146A/es unknown
-
2002
- 2002-06-25 US US10/179,717 patent/US6608218B2/en not_active Expired - Fee Related
-
2003
- 2003-01-07 ZA ZA200300173A patent/ZA200300173B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004504388A5 (cg-RX-API-DMAC7.html) | ||
| JP2004521095A5 (cg-RX-API-DMAC7.html) | ||
| RU2002118339A (ru) | Транс-олефиновые активаторы глюкокиназы | |
| JP2006515858A5 (cg-RX-API-DMAC7.html) | ||
| CA2430579A1 (en) | Isoindolin-1-one glucokinase activators | |
| CA2565813A1 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| JP2004506632A5 (cg-RX-API-DMAC7.html) | ||
| CA2407428A1 (en) | Hydantoin-containing glucokinase activators | |
| JP2005501120A5 (cg-RX-API-DMAC7.html) | ||
| RU98100866A (ru) | Ароматические соединения и содержащие их фармацевтические композиции | |
| WO1992009279A1 (fr) | Derive de 2-arylthiazole et composition pharmaceutique contenant ce derive | |
| JP2004502670A5 (cg-RX-API-DMAC7.html) | ||
| CA2482346A1 (en) | Substituted phenylacetamides and their use as glucokinase activators | |
| CA2413313A1 (en) | Antitumor effect potentiators | |
| CA2535749A1 (en) | Ppar activating compound and pharmaceutical composition containing same | |
| WO2011035900A1 (en) | New thiadiazole derivatives | |
| CA2453747A1 (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use | |
| JP2005526696A5 (cg-RX-API-DMAC7.html) | ||
| CA2461916A1 (en) | Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis | |
| JP2010506919A5 (cg-RX-API-DMAC7.html) | ||
| JP2023062064A5 (cg-RX-API-DMAC7.html) | ||
| WO2004093806A3 (en) | Compounds for the treatment of metabolic disorders | |
| RU2004129285A (ru) | Производные тиазола в качестве антагонистов рецептора npy | |
| JP2005515976A5 (cg-RX-API-DMAC7.html) | ||
| EP1398313A4 (en) | NEW HETEROCYCLIC DERIVATIVES AND THEIR MEDICAL USE |